XML 60 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Deferred income tax assets:    
Net operating loss carryforward $ 82,784,742 $ 79,788,146
Research and orphan drug credits 51,184,585 47,976,370
Capitalized research costs 7,125,276  
Capitalized start-up costs 726,724 920,516
Patent amortization 58,010 73,480
Stock-based compensation 7,247,715 7,102,947
Accrued bonus 733,235 592,260
Operating lease liabilities 252,777 528,340
Other 210,237 209,580
Gross deferred income tax assets 150,323,301 137,191,639
Valuation allowance (149,972,514) (136,613,829)
Net deferred income tax assets 350,787 577,810
Deferred tax liabilities:    
Operating lease right-of-use assets (206,704) (433,727)
Property and equipment (144,083) (144,083)
Gross deferred income tax liabilities (350,787) (577,810)
Net deferred income tax asset/(liability)